Side-by-side · Research reference
HCGvsOvagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED12/52 cited
BTheoreticalHUMAN-REVIEWED2/42 cited
HCG
Glycoprotein Hormone · LH Mimetic
IM or SQ · 2–3×/week
Ovagen
Khavinson Bioregulator · Ovarian
OvarianTarget tissue
Di/Tri-peptidePeptide length
AnimalEvidence tier
Oral / SQ · Protocol varies
01Mechanism of Action
Parameter
HCG
Ovagen
Primary target
LH receptors on testicular Leydig cellsSchröder-Lange 2025
Ovarian tissue chromatin complexes
Pathway
hCG → Leydig cell LH receptor → Intracellular cAMP → Steroidogenesis pathway activation → Testosterone synthesis
Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation
Downstream effect
Elevated intratesticular testosterone, restored spermatogenesis, virilization, secondary sex characteristic developmentKonsam 2026Zachariou 2026
Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration
Feedback intact?
No — exogenous hCG bypasses hypothalamic-pituitary axis; endogenous LH remains suppressed
Presumed physiological — Khavinson peptides described as regulatory, not replacement
Origin
Heterodimeric glycoprotein (alpha subunit shared with LH/FSH/TSH; beta subunit confers specificity). Available as urinary-derived or recombinant formulations.
Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)
Antibody development
Rare with recombinant; possible with urinary-derived formulations
—
02Dosage Protocols
Parameter
HCG
Ovagen
Hypogonadotropic hypogonadism (monotherapy)
2,000 IU IM/SQ 2–3×/weekKonsam 2026Zachariou 2026
Titrate to normalize testosterone (300–1,000 ng/dL) or achieve target AMH ~7.4 ng/mL.
—
Combined therapy (hCG + FSH)
hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wkKonsam 2026Nariyoshi 2025
Preferred for azoospermia; FSH added after initial hCG phase or from outset.
—
Triple therapy (experimental)
hCG 2,000 IU 2×/wk + rFSH 75 IU 3×/wk + testosterone 100 mg IM q2wkKonsam 2026
May accelerate virilization; reduces hCG requirements (~30% lower cumulative dose vs monotherapy).
—
Cryptorchidism (pediatric)
500–4,000 IU IM 2–3×/week for 3–6 weeks
—
Evidence basis
RCT / Meta-analysis / FDA-approvedKonsam 2026Huijben 2026
Theoretical / Russian-tradition
Duration to sperm appearance
12–24 months (median ~18 mo)Huijben 2026Zachariou 2026
Congenital HH may require longer treatment; acquired HH responds faster.
—
Route
Intramuscular or subcutaneousKonsam 2026
Oral (capsule) or subcutaneous
Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.
Monitoring
Serum testosterone, semen analysis q3–6mo, testicular ultrasound
Thickened seminiferous tubules (>300 μm) on ultrasound predict imminent sperm appearance.Nariyoshi 2025
—
Standard dose
—
10–20 mg / day (oral) or 1–2 mg SQ
Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.
Frequency
—
Once daily or cyclical (10–20 days per month)
Cyclical protocols common in Khavinson bioregulator tradition.
Duration
—
4–12 weeks per cycle
Khavinson protocols typically 1–3 months; repeat cycles as needed.
04Side Effects & Safety
Parameter
HCG
Ovagen
Injection site reaction
Pain, erythema (mild, transient)
Possible mild erythema (SQ route)
Gynecomastia
Aromatization of elevated testosterone to estradiol; dose-dependent
—
Testicular discomfort / Edema
Rapid testicular growth in hypogonadal males; usually self-limiting
—
Polycythemia
Elevated hematocrit from supraphysiological testosterone; monitor CBC
—
Mood / Libido changes
Variable; usually positive with normalization of testosterone
—
Acne / Oily skin
Androgen-mediated; dose-dependent
—
Prostate concerns
Monitor PSA in older males; hCG restores physiological testosterone (not supraphysiological)
—
Antibody formation
Rare with recombinant; possible with urinary-derived
—
Reported adverse events
—
None documented in indexed literature
Theoretical hormonal effects
—
Ovarian stimulation — monitor for estrogen-sensitive conditions
Long-term safety
—
Unknown — no PubMed-indexed RCTs
Absolute Contraindications
HCG
- ·Androgen-dependent malignancy (prostate, breast cancer)
- ·Hypersensitivity to hCG or excipients
- ·Precocious puberty
Ovagen
- ·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
- ·Pregnancy
Relative Contraindications
HCG
- ·Untreated obstructive sleep apnea
- ·Severe cardiovascular disease (polycythemia risk)
- ·History of thromboembolism
Ovagen
- ·History of estrogen-sensitive tumors (monitor)
- ·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
- ·Endometriosis or fibroids (estrogen-responsive conditions)
05Administration Protocol
Parameter
HCG
Ovagen
1. Reconstitution (if lyophilized)
Add sterile water or bacteriostatic water per manufacturer instructions. Typically 1–2 mL per 5,000–10,000 IU vial. Roll gently — do not shake. Solution should be clear.
Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.
2. Injection site
Intramuscular: ventrogluteal, vastus lateralis, or deltoid. Subcutaneous: abdomen, avoiding navel (2-inch radius). Rotate sites to prevent lipohypertrophy.
1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.
3. Timing
Administer 2–3 times per week. Consistent weekly schedule recommended (e.g., Monday/Thursday or Monday/Wednesday/Friday).
Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.
4. Storage
Lyophilized: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C. Bacteriostatic water extends shelf life to ~30 days; sterile water use within 72 hours.
Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.
5. Needle selection
IM: 21–23G, 1–1.5 inch. SQ: 25–27G, 5/8 inch. Inject slowly (30–60 seconds for IM).
—